FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) is an explanation video about research on the new coronavirus infection (COVID-19) using our AI system "Cascade Eye". Will be published.

The commentary video will be updated once a week and will be released 1 times in total.The first session was entitled "FRONTEO-COMBAT COVID-10- (1) Outline of Search for Candidate Drugs Utilizing AI", and Hiroyoshi Toyoshiba, CTO of our Life Science AI CTO, explained the outline of this research. I will.

≪Public URL≫

https://lifescience.fronteo.com/covid-19

≪Title to be released≫

1st Outline of search for candidate drugs using AI

2nd FRONTEO AI-based candidate drug search method

COVID-3 search by the 19rd "Cascade Eye"

Results of the 4th search (10) NATXNUMX inhibitor

5th search result (XNUMX) TOP inhibitor

6th search result (XNUMX) MUTYH

7th search result (1) JAKXNUMX inhibitor and human search

8th search result (19) Difference between SARS and COVID-XNUMX

9th search result (XNUMX) About antiviral agents

10th Intelligence for Infectious Disease Pandemic

* Title, content, and order are subject to change.

FRONTEOEfforts for the new coronavirus infection "COMBAT COVID-19"about

At FRONTEO, we are implementing initiatives for new coronavirus infections that utilize our AI.Information on this matter and future activities will be released on the special website below.The pathway map created by FRONTEO is widely available to pharmaceutical companies and public institutions so that it can be used to select therapeutic agents.

https://lifescience.fronteo.com/covid-19

Cascade Eyeabout　URL:https://lifescience.fronteo.com/pharmaceuticals/cascade-eye/

"Cascade Eye" analyzes papers and medical information using FRONTEO's natural language analysis AI engine "Concept Encoder", and displays important genes and molecules involved in diseases on a pathway map (path map showing relevance). It is an AI system that visualizes.By analyzing the papers on the molecules and genes shown on the map, it is possible to search for existing drug candidates.Since AI makes decisions without human assumptions or biases, it can be applied comprehensively to predicting efficacy and safety, in addition to discovering new targets and biomarkers that may be overlooked only with existing knowledge and experience. is.We believe that it will be useful for discovering therapeutic agents for diseases with high unmet medical needs (medical needs for diseases for which there is no effective treatment method yet) and for selecting therapeutic agent candidates in a short period of time when a virus pandemic occurs.

concept encoderabout　URL: https://lifescience.fronteo.com/concept-encoder/

"Concept Encoder (concept encoder)^®, Concept Encoder) ”is a natural language analysis AI (artificial intelligence) developed by FRONTEO specializing in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO Inc. has developed its own natural language analysis AI (artificial intelligence) engine "KIBIT".^®(Kibit) ”and“ concept encoder^®(Concept encoder) ”is a company that supports information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves evidence, investigates and analyzes electronic data necessary for international proceedings, and digital forensic investigations, and technologies such as an in-house developed data analysis platform To date, we have supported about 8 international proceedings.In addition, we are applying the unique AI-related technology cultivated in the legal business to areas such as life science and business intelligence, and have achieved results in drug discovery research support, diagnostic support, and work style reform. Listed on TSE Mothers on June 1, 2007.The capital is 6 thousand yen (as of March 26, 2,559,206).